Parcel Bio Analysis: $500K Raised
What is Parcel Bio?
Parcel Bio focuses on developing next-generation RNA medicines to advance therapeutic solutions.
How much Parcel Bio raised
February 14, 2024 - $500,000
Lead Investor: 10 BOND and 5 other investors
Who are the founders of Parcel Bio
DW
David Weinberg
Founder, CEO
CC
Chris Carlson
Founder, CSO
Market Focus
Parcel Bio primarily focuses on the biotechnology industry, specifically in the development and delivery of RNA medicines.
Investors
- Alumni Ventures
- Lexi Ventures
- Metaplanet Holdings
- North South Ventures
- Pioneer Fund
- Y Combinator
- Ritual Capital
- SBXi
Competitors Overview
Parcel Bio operates in the RNA medicine market, which has several notable competitors, including:
- Alnylam Pharmaceuticals:
- Overview: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, focusing on silencing genes that contribute to diseases. They have developed several FDA
See something that needs updating? Suggest edits to this profile.